Ibogaine, an alkaloid derived from the root bark of the West African shrub Tabernanthe iboga, has been a subject of considerable interest and debate due to its psychoactive properties and potential therapeutic uses, particularly in treating addiction. The legality of ibogaine varies significantly around the world, reflecting diverse cultural attitudes, legal frameworks, and medical paradigms.
In some Western countries, ibogaine is classified as a Schedule I substance under their respective Controlled Substances Acts. This classification indicates that it is regarded as having a high potential for abuse, no currently accepted medical use in treatment, and a lack of accepted safety for use under medical supervision. For instance, in the United States, ibogain